RNA-mediated neurodegeneration in fragile X-associated tremor/ataxia syndrome

Brain Res. 2012 Jun 26:1462:112-7. doi: 10.1016/j.brainres.2012.02.057. Epub 2012 Mar 9.

Abstract

Carriers of fragile X syndrome (FXS) have FMR1 alleles, called premutations, with a number of 5'-untranslated-CGG repeats somewhere between patients, who have over 200 repeats, and normal individuals, with fewer than 60 repeats. Fragile X-associated tremor/ataxia syndrome (FXTAS), a late-onset neurodegenerative disorder, has been recognized in older male fragile X premutation carriers, and FXTAS is uncoupled from the neurodevelopmental disorder, FXS. Several lines of evidence have led to the proposal of an RNA (fragile X premutation rCGG repeat)-mediated gain-of-function toxicity model for FXTAS, in which rCGG repeat-binding proteins (RBPs) could become functionally limited by their sequestration to lengthy rCGG repeats. In this review, we will discuss the recent progress towards understanding the molecular basis of RNA-mediated neurodegeneration in FXTAS. This article is part of a Special Issue entitled: RNA-Binding Proteins.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Alleles
  • Ataxia / genetics
  • Ataxia / pathology
  • Fragile X Mental Retardation Protein / genetics
  • Fragile X Syndrome / drug therapy
  • Fragile X Syndrome / genetics*
  • Fragile X Syndrome / pathology
  • Heterozygote
  • Humans
  • Nerve Degeneration / drug therapy
  • Nerve Degeneration / genetics*
  • Nerve Degeneration / pathology
  • RNA / physiology*
  • Tremor / genetics
  • Tremor / pathology
  • Trinucleotide Repeats / genetics

Substances

  • Fragile X Mental Retardation Protein
  • RNA